Entera Bio LTD

Entera Bio Ltd. announced the appointment of Dr. Riccardo Paolo Camisasca as Chief Medical Officer, bolstering its clinical leadership for upcoming Phase 3 trials.

Entera Bio Ltd. announced a $275 million private placement and positive FDA feedback for its oral osteoporosis drug EB613, positioning it for Phase 3 trials and NDA submission.

Entera Bio Ltd. announced a $275 million private placement of ordinary shares and pre-funded warrants to institutional and accredited investors, including funds affiliated with BVF Partners L.P.

Entera Bio Ltd. shareholders approved an increase in authorized shares and an amendment to the equity incentive plan at the 2026 Annual Meeting.

Entera Bio Ltd. announced a $10 million private placement of units, comprising ordinary shares and warrants, to funds affiliated with BVF Partners LP.

Entera Bio announced its full year 2025 financial results and provided key business updates, highlighting progress in its oral peptide development programs, particularly EB613 for osteoporosis.

Entera Bio Ltd. reported its Q2 2026 results, highlighting a substantial $275 million capital raise and progress in its EB613 osteoporosis drug development, alongside increased R&D expenses and continued net losses.

Entera Bio reports Q1 2026 financial results, highlighting progress on its oral peptide pipeline and a $10 million private placement to support Phase 3 development.

Entera Bio Ltd. reported increased operating losses for Q3 and the nine months ended September 30, 2025, despite advancing its oral peptide pipeline and securing new funding through a collaboration with OPKO.

Entera Bio Ltd. reported increased operating losses but secured significant financing and advanced its lead osteoporosis and obesity drug candidates, though substantial doubt remains about its ability to fund future operations.

Entera Bio Ltd. reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and a new collaboration agreement with OPKO.

Entera Bio's Q3 2024 report shows a net loss of $3.021 million, with ongoing research and development efforts and a focus on oral peptide therapies.

Entera Bio Ltd. reported increased net losses and declining revenue in 2025, raising substantial doubt about its ability to continue as a going concern without significant additional funding.

Entera Bio Ltd. files its 10-K report for the fiscal year ended December 31, 2024, highlighting its focus on developing oral peptide therapies and its plans for advancing key programs.

Entera Bio Ltd. released its annual 10-K filing, detailing advancements in its oral peptide programs for osteoporosis and hypoparathyroidism, and a new collaboration with OPKO Biologics.

Steven D Rubin, a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Yonatan Malca, a Director of Entera Bio Ltd., received 22,815 shares of common stock on August 7, 2026.

Haya Taitel, a Director of Entera Bio Ltd., received 20,790 shares of common stock on August 7, 2026.

Sean Ellis, a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd., received 140,000 shares of common stock on August 7, 2026.

Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd., received 200,000 shares of common stock on August 7, 2026.

Entera Bio Ltd. announced its 2026 Annual Meeting of Shareholders, set for July 14, 2026, to vote on director elections, executive and non-executive director compensation, and amendments to equity plans and articles of association.

Entera Bio Ltd. has announced its upcoming Annual Shareholder Meeting on July 16, 2025, where shareholders will vote on the election of a Class II director, ratification of executive compensation, and the appointment of independent auditors.

Entera Bio Ltd. is seeking shareholder approval for significant executive compensation increases and an updated compensation policy, following a year of substantial shareholder return growth despite a widening net loss.

Entera Bio Ltd. will hold its annual shareholder meeting on July 31, 2024, to vote on director elections, executive compensation, and other corporate matters.

Entera Bio is holding its 2024 Annual Meeting of Shareholders on July 31, 2024, to vote on director elections, executive compensation, an amendment to the 2018 Equity Incentive Plan, and other corporate governance matters.

Entera Bio Ltd. announces significant capital raise and grants board designation rights to Biotechnology Value Fund L.P. and its affiliates.

Longitude Capital Partners V, LLC and related entities report a 4.6% beneficial ownership stake in Entera Bio Ltd. ordinary shares.

Seven Fleet Horizon Master Fund LP, Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Brian Liu have collectively reported a change in their beneficial ownership of Entera Bio, Ltd. ordinary shares.

TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have jointly filed a Schedule 13G, reporting beneficial ownership of 12,254,901 ordinary shares, representing 7.1% of Entera Bio Ltd.'s outstanding shares.

Several Vivo Opportunity entities have updated their beneficial ownership filings for Entera Bio Ltd., reflecting significant holdings and voting power.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 2.6% beneficial ownership stake in Entera Bio Ltd. as of September 30, 2025.

OPKO Health, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 8.1% of Entera Bio Ltd.'s ordinary shares, totaling 3,685,226 shares, as of March 16, 2025.